docetaxel anhydrous has been researched along with naphthoquinones in 7 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (naphthoquinones) | Trials (naphthoquinones) | Recent Studies (post-2010) (naphthoquinones) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 7,110 | 149 | 2,923 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hatakeyama, S; Kinoyama, I; Kita, A; Koutoku, H; Matsuhisa, A; Nakahara, T; Nakano, K; Sasamata, M; Shishido, T; Takeuchi, M; Yamanaka, K | 1 |
| Kaneko, N; Kita, A; Kiyonaga, F; Nakahara, T; Sasamata, M; Takeuchi, M; Yamanaka, K; Yamauchi, T | 1 |
| Akabane, T; Kaneko, N; Kita, A; Mori, M; Tabata, K; Yamanaka, K | 1 |
| Chen, C; Chmielowski, B; Ernst, S; Gonzalez, R; Jie, F; Keating, A; Kudchadkar, R; Redman, BG; Steinberg, J; Weber, J | 1 |
| Clemens, MR; Crown, J; Gartner, E; Gladkov, OA; Jie, F; Keating, A; Steinberg, J; Vladimirov, V | 1 |
| Kulkarni, AB; Liu, B; Sun, ZJ; Wang, YF; Zhang, L; Zhang, W; Zhang, WF; Zhao, YF | 1 |
| Chen, L; Chen, W; Feng, J; Lin, F; Liu, Y; Meng, Q; Wang, H; Zhang, G; Zhang, Y; Zhu, Z | 1 |
2 trial(s) available for docetaxel anhydrous and naphthoquinones
| Article | Year |
|---|---|
A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Naphthoquinones; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Treatment Outcome | 2015 |
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Lymphatic Metastasis; Middle Aged; Naphthoquinones; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2015 |
5 other study(ies) available for docetaxel anhydrous and naphthoquinones
| Article | Year |
|---|---|
YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Mice; Mice, Nude; Mitosis; Naphthoquinones; Survivin; Taxoids; Xenograft Model Antitumor Assays | 2011 |
Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Caspase 7; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Male; Melanoma; Mice; Mice, Nude; Naphthoquinones; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Survivin; Taxoids; Xenograft Model Antitumor Assays | 2011 |
Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Mice; Mice, Nude; Naphthoquinones; Survivin; Taxoids; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Imidazoles; In Situ Nick-End Labeling; Inhibitor of Apoptosis Proteins; Lysosomal-Associated Membrane Protein 2; Membrane Proteins; Mice; Mice, Knockout; Mice, Nude; Microtubule-Associated Proteins; Mitochondria; Naphthoquinones; Phosphorylation; Retinoblastoma Protein; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Survivin; Tamoxifen; Taxoids; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
AS1411 Aptamer/Hyaluronic Acid-Bifunctionalized Microemulsion Co-Loading Shikonin and Docetaxel for Enhanced Antiglioma Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aptamers, Nucleotide; Cell Line; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Emulsions; Glioma; Humans; Hyaluronic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Naphthoquinones; Nucleolin; Oligodeoxyribonucleotides; Phosphoproteins; RNA-Binding Proteins; Tissue Distribution | 2019 |